DaVita Stock (DVA)

XNYS Alert Compare

Health Care · Fundamental analysis

DaVita's revenue has grown by 3.4% a year over the last 5 years – slower than the median of the Health Care sector (+8.5%). The net margin in the last fiscal year was 5.5%, the sector median 13.9%. The 52-week high is 53.7% away (close of Nov 20, 2026).

· How we analyze

Metrics from daily candles, as of Nov 20, 2026 · Extended universe

Figures in the price bar from TradingView (mostly trailing 12 months) · our fundamental analysis uses the fiscal year

At a glance: figures and chart

1 strength · 1 weakness · Fiscal year to Dec 31, 2025
Quality checks from the annual figures and, separately, the position of the price relative to the 200-day line. No overall score.
  • Quality 2 of 6 criteria with data met · 2 without data
  • Growth 5 of 6 criteria with data met · 1 without data
  • Dividend 0 of 1 criteria with data met · 6 without data
  • Financial strength 3 of 5 criteria with data met · 1 without data
Chart position more than 10% below – position relative to the 200-day line

Strengths well above the threshold

  • EPS growth 5 years +9.3% per year Threshold: above 5% per year · Distance +4.3 pp · Sector median +8.3% per year (47 stocks) · Fiscal year to Dec 31, 2025

Weaknesses well below the threshold

  • Equity −651.1M USD Threshold: above 0 · Fiscal year to Dec 31, 2025

On the radar

  • Position relative to the 200-day line: more than 10% below (as of Nov 20, 2026)
  • Net margin 5.5% – Threshold: above 10%, distance −4.5 pp (Fiscal year to Dec 31, 2025)
  • Free cash flow margin 9.6% – Threshold: above 10%, distance −0.4 pp (Fiscal year to Dec 31, 2025)

What we do not know

  • Data missing: 4 of 28 criteria not stated in the SEC filings (Fiscal year to Dec 31, 2025).
    • Gross margin above 40%
    • Return on equity above 15%
    • Over 10 years, revenue grew by more than 5% per year
    • Piotroski F-Score at least 7 of 9

Not applicable

  • Pays no dividend – the dividend criteria do not apply (Fiscal year to Dec 31, 2025).
  • Return on equity and debt / equity: not computable because equity is negative (Fiscal year to Dec 31, 2025).

How is this made? · Created on Nov 22, 2026 from fixed rules · not investment advice

Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Academy: 200-day line · RSI

About the company

DaVita runs dialysis centers for people with kidney failure, mainly in the US and in some other countries. It also offers home dialysis and care programs for kidney patients. The investor Berkshire Hathaway is the main shareholder. As of Oct 13, 2026

Fact sheet (from the annual report) Other health services · Denver, USA

DaVita sees itself as a comprehensive kidney care provider, from slowing the disease to supporting transplants. Patients are treated in its own dialysis centers, in hospitals, in care facilities and at home. In addition, there is its own specialty laboratory for patients with end-stage kidney failure as well as services for contractually agreed fees for dialysis centers in which the company holds at most a minority stake. The DaVita Integrated Kidney Care (IKC) division manages the care of members with chronic kidney disease for health insurers and government programs, in part under risk-based contracts. Other areas are clinical contract research, software for transplants and outpatient dialysis centers abroad.

Automatically summarized from SEC annual report (10-K, filed Feb 11, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026

What the methods say about DaVita

This symbol belongs to the extended universe: we load daily candles only and show metrics, fundamentals and an overview – chart methods and Elliott analysis are not available for it.

Calculated automatically by fixed rules – not investment advice, check for yourself. How we analyze

Price performance at a glance

Last 30 trading days
  • Today +3.0%
  • 7 days −7.8%
  • 30 days −8.9%
  • 1 year +39.6%
Day range (last trading day)
−2.4%Price at 66% of the range+1.2%
52-week range
−37.3%Price at 41% of the range+53.7%
Distance from the all-time high
−34.9%

Our own calculation from the exchange’s daily candles, as of Nov 20, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Chart analysis: trend by timeframe

  1. 1W weekly candles mixed
    • Close above the SMA 200
    • EMA 20 above the EMA 50
    • Highs and lows mixed

    Price below the EMA 20 · below the EMA 50

    Week to Nov 20, 2026

  2. 1D daily candles mixed
    • Close below the SMA 200
    • EMA 20 below the EMA 50
    • Highs and lows mixed

    Price below the EMA 20 · below the EMA 50

    Daily candle of Nov 20, 2026

  3. 4H 4-hour candles not available

    No value on 4 hours (too few or no checked 4-hour candles).

Rule per timeframe: up = close above the SMA 200, EMA 20 above the EMA 50 and higher highs and lows; down = everything the other way round; otherwise mixed. Completed candles only, no overall score, no forecast. In the screener: all three up

What does the daily chart show right now – line by line, without an overall verdict?

Technicals in plain words

Over the last 3 months it ran stronger than the S&P 500 and weaker than the median of the sector “Health Care”.

vs. S&P 500 · 3 months
stronger
vs. S&P 500 · 6 months
weaker
vs. sector · 3 months
weaker
  • Trend below SMA 200 Price below the 200-day line – below it the long-term trend counts as down; ADX below 20 – hardly any trend.
  • Momentum neutral RSI between 30 and 70 – neither overbought nor oversold; MACD line below its signal line (gap below 0).
  • Volume not elevated Volume on the last trading day below 1.5 times the average of up to 50 trading days before – not elevated.
  • Volatility high Typical daily range (ATR 14) above 4% of the price – high.

The figures behind it – distance to the line, RSI, volume, volatility and relative strength in percentage points – are visible with a free account. Sign up free

More depth

How we read the lines

  • Each line stands on its own – we do not add them up and give no grade.
  • Trend: the 200-day line is the average of the last 200 closing prices. The ADX (14) measures how pronounced a trend is, not its direction: below 20 hardly any trend, above 25 pronounced.
  • Momentum: the RSI (14) lies between 0 and 100; below 30 it counts as oversold, above 70 as overbought. The MACD (12/26) compares two averages, the signal line (9) smooths it.
  • Volume: shares traded on the last trading day divided by the average of up to 50 trading days before; from 1.5x elevated, from 2x unusually high, from 3x very high.
  • Volatility: typical daily range (ATR 14) as a percentage of the price; below 2% calm, 2 to 4% normal, above 4% high. Squeeze = Bollinger Bands as narrow as on at most a fifth of the last 120 trading days.
  • Relative strength: the stock’s price change minus that of the benchmark over the same period (3 months = 91 days, 6 months = 182 days), in percentage points, from completed daily candles. Benchmark: the S&P 500 (ETF SPY) or the median of the stocks of the same sector in our selection (at least 5 others with a candle on the same day). Dividends are not included.
  • Against the sector median over 6 months: ran weaker.
  • All figures describe the price history so far – they do not say what happens next.

In the screener: stocks that ran stronger than the S&P 500 over 3 months

As of: daily candle of Nov 20, 2026 · from our daily candles

How did this asset do in each calendar month over the last 10 years?

Seasonality

In November, the stock closed higher in 8 of 10 years – the S&P 500 in 9 of 10.

Years higher in November
8 of 10
2016 to 2025
S&P 500 in November
9 of 10
years higher, same years as above (ETF SPY)
Months mostly higher
7 of 12
Calendar months that closed higher in more than half of the years

You can see the median and range per month in percent with a free account. Sign up free

  • January: higher in 6 of 10 years
  • February: higher in 5 of 10 years
  • March: higher in 4 of 10 years
  • April: higher in 7 of 10 years
  • May: higher in 6 of 10 years
  • June: higher in 6 of 10 years
  • July: higher in 6 of 10 years
  • August: higher in 4 of 10 years
  • September: higher in 4 of 10 years
  • October: higher in 4 of 10 years
  • November (current month): higher in 8 of 10 years
  • December: higher in 7 of 10 years
Past performance, not a forecast · Bar = share of years higher, line = half · Price return without dividends
More depth

How we calculate

  • Monthly return = closing price on the last trading day of the month ÷ closing price on the last trading day of the previous month − 1. Price return without dividends.
  • Only completed months count, never the current one. If the candle of the last trading day is missing, the month does not count.
  • For each calendar month the last 10 years in which it has ended; from 8 years with a value we show the median, years higher and the range. “Higher” means: return above 0.0%.
  • Past performance, not a forecast: the figures describe earlier years and do not tell how the next month will go.
By calendar month (● = current month)
MonthYears higher
January6 of 10
February5 of 10
March4 of 10
April7 of 10
May6 of 10
June6 of 10
July6 of 10
August4 of 10
September4 of 10
October4 of 10
November ●8 of 10
December7 of 10

Through October 2026 (last completed month) · from our daily candles

Fundamental analysis

DaVita · Sector Health Care · amounts in USD

Source: SEC filings, As of Feb 11, 2026.

For you first Dividend

The company paid no dividend in fiscal year 2025.

For you first Valuation

The P/E is about at its own median of the 5 fiscal years before.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

For you first Growth

How strongly revenue and earnings per share have grown over the years.

Check “Growth”
5 of 6
criteria with data met
Revenue per year (5 y)
+3.4%
EPS per year (5 y)
+9.3%

For you first Quality

How much of revenue remains and whether profit arrives as cash.

Check “Quality”
2 of 6
criteria with data met
Net margin
5.5%
Cash flow ÷ profit
1.75x
backed from 1.0 · 3 years: 1.82x

For you first Trading

Trend by timeframe under a fixed rule – direction, not a forecast.

weekly candles
mixed
daily candles
mixed

Quality checks

Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.

Fiscal year to Dec 31, 2025

Quality 2 of 6 met · 2 without data

  • no data: Gross margin above 40% not stated in the SEC filings
  • not met: Operating margin above 15% 15.0%
  • not met: Net margin above 10% 5.5%
  • no data: Return on equity above 15% negative equity
  • not met: Free cash flow margin above 10% 9.6%
  • met: Profit in each of the last 5 fiscal years 5 of 5
  • met: Free cash flow positive in each of the last 3 fiscal years 3 of 3
  • not met: Equity ratio above 30% −3.7%
Operating margin

15.0% Fiscal year 2025

Rank 48 of 100: higher than 48% of 470 peers (All). medium.

Rank 47 of 100: higher than 47% of 54 peers (Sector). medium.

Median Health Care: 17.0%

Operating income divided by revenue: what the core business earns before interest and taxes.

Net margin

5.5% Fiscal year 2025

Rank 28 of 100: higher than 28% of 584 peers (All). weak.

Rank 26 of 100: higher than 26% of 63 peers (Sector). weak.

Median Health Care: 12.9%

Profit after all costs, interest and taxes divided by revenue.

Return on assets

4.3% Fiscal year 2025 (total assets at year end)

Rank 44 of 100: higher than 44% of 594 peers (All). medium.

Rank 33 of 100: higher than 33% of 63 peers (Sector). medium.

Median Health Care: 6.6%

Net income divided by total assets at fiscal year end.

Equity ratio

−3.7% Fiscal year 2025

Rank 4 of 100: higher than 4% of 595 peers (All). weak.

Rank 7 of 100: higher than 7% of 63 peers (Sector). weak.

Median Health Care: 44.2%

Equity as a share of total assets. Usually low for banks.

Free cash flow margin

9.6% Fiscal year 2025

Rank 45 of 100: higher than 45% of 465 peers (All). medium.

Rank 30 of 100: higher than 30% of 61 peers (Sector). weak.

Median Health Care: 14.5%

Free cash flow divided by revenue.

Free cash flow

1.3B USD Fiscal year 2025

Operating cash flow minus capital expenditure on property and equipment.

Growth 5 of 6 met · 1 without data

  • met: Over 3 years, revenue grew by more than 5% per year +5.5%
  • not met: Over 5 years, revenue grew by more than 5% per year +3.4%
  • no data: Over 10 years, revenue grew by more than 5% per year no comparable figures over 10 years
  • met: Over 3 years, EPS grew by more than 5% per year +18.9%
  • met: Over 5 years, EPS grew by more than 5% per year +9.3%
  • met: Revenue rose in at least 4 of the last 5 fiscal years 4 of 5
  • met: Revenue rose in the last fiscal year +6.5%
Revenue growth 3 years

+5.5% per year

Rank 47 of 100: higher than 47% of 578 peers (All). medium.

Rank 54 of 100: higher than 54% of 62 peers (Sector). medium.

Median Health Care: +5.1%

Average growth per year over 3 fiscal years.

Revenue growth 5 years

+3.4% per year

Rank 18 of 100: higher than 18% of 549 peers (All). weak.

Rank 16 of 100: higher than 16% of 60 peers (Sector). weak.

Median Health Care: +7.8%

Average growth per year over 5 fiscal years.

EPS growth 3 years

+18.9% per year

Rank 74 of 100: higher than 74% of 437 peers (All). strong.

Rank 75 of 100: higher than 75% of 54 peers (Sector). strong.

Median Health Care: +5.0%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 5 years

+9.3% per year

Rank 42 of 100: higher than 42% of 399 peers (All). medium.

Rank 56 of 100: higher than 56% of 47 peers (Sector). medium.

Median Health Care: +8.3%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 10 years

+22.9% per year

Rank 91 of 100: higher than 91% of 375 peers (All). strong.

Rank 90 of 100: higher than 90% of 46 peers (Sector). strong.

Median Health Care: +9.3%

Growth of earnings per share per year, adjusted for stock splits.

Dividend 0 of 1 met · 6 without data

  • not met: Pays a dividend no dividend per share reported for the last fiscal year
  • no data: Payout ratio at most 60% of earnings pays no dividend
  • no data: Dividend paid in each of the last 5 fiscal years pays no dividend
  • no data: Dividend per share never lowered in the last 5 fiscal years pays no dividend
  • no data: Dividend per share higher than 5 years ago pays no dividend
  • no data: Free cash flow per share covers the dividend pays no dividend
  • no data: Dividends paid over the last 5 years covered by free cash flow pays no dividend

Financial strength 3 of 5 met · 1 without data

  • no data: Piotroski F-Score at least 7 of 9 too many criteria without data 6 of 8 · 1 without data
  • not met: Long-term debt no higher than equity negative equity
  • met: Current assets cover current liabilities 1.29
  • not met: Positive equity −651.1M USD
  • met: In 5 years, share count up by at most 5% −38.1%
  • met: Free cash flow positive in the last fiscal year 1.3B USD
Piotroski F-Score

6 of 8 Fiscal year 2025

No rank: not all 9 criteria have data.

Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.

Debt / equity

negative equity at fiscal year end

No rank: too few peers or not computed yet.

Long-term financial debt divided by equity.

Liquidity (current ratio)

1.29 at fiscal year end

Rank 49 of 100: higher than 49% of 513 peers (All). medium.

Rank 34 of 100: higher than 34% of 63 peers (Sector). medium.

Median Health Care: 1.58

Current assets divided by current liabilities.

Change in share count

−38.1% in 5 years

Rank 99 of 100: lower than 99% of 507 peers (All). strong.

Rank 99 of 100: lower than 99% of 59 peers (Sector). strong.

Median Health Care: −4.3%

Change in diluted share count. Negative = share buybacks, positive = new shares.

The 9 criteria of the Piotroski F-Score
  • met: Profit in the last fiscal year (positive return on assets)
  • met: Positive operating cash flow
  • not met: Return on assets higher than the prior year
  • met: Operating cash flow higher than net income
  • not met: Long-term debt relative to total assets fell
  • met: Liquidity (current assets / current liabilities) rose
  • met: No additional shares (diluted share count did not rise)
  • no data: Gross margin higher than the prior year
  • met: Revenue relative to total assets higher than the prior year

Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.

Price-based criteria (P/E, dividend yield) are shown to signed-in users.

Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.

In short

  • Light yellow: Revenue grew over 5 years (+3.4% per year), more slowly than the sector median.
  • Light red: Net income (total) shrank over 5 years (−0.7% per year); per share +9.3% per year.
  • Light yellow: Net margin 5.5%, below the sector median (13.9%).
  • Light green: Profit in each of the last 10 fiscal years.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 10.7B USD · Net income 879.9M USD · Net margin 8.2%
  2. Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 10.9B USD · Net income 663.6M USD · Net margin 6.1%
  3. Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 11.4B USD · Net income 159.4M USD · Net margin 1.4%
  4. Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 11.4B USD · Net income 811.0M USD · Net margin 7.1%
  5. Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 11.6B USD · Net income 773.6M USD · Net margin 6.7%
  6. Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 11.6B USD · Net income 978.5M USD · Net margin 8.4%
  7. Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 11.6B USD · Net income 560.4M USD · Net margin 4.8%
  8. Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 12.1B USD · Net income 691.5M USD · Net margin 5.7%
  9. Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 12.8B USD · Net income 936.3M USD · Net margin 7.3%
  10. Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 13.6B USD · Net income 746.8M USD · Net margin 5.5%

Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 13.6B USD · Net income 746.8M USD · Net margin 5.5%

How has it gone since the last annual report?

Trailing 12 months and quarters

Revenue in the quarter to Sep 2026 +4.6% vs. the same quarter a year earlier; grown for 15 quarters in a row.

Revenue 12 months vs. prior 12
+6.4%
12 months: 14.2B USD · Fiscal year 2025: +6.5%
Net margin 12 months
6.5%
Fiscal year 2025: 5.5%
Free cash flow margin 12 months
9.1%
Fiscal year 2025: 9.6%
More depth

Calculation of the 12 months to Sep 30, 2026

  • Revenue: fiscal year to Dec 31, 2025 13.6B USD + year to date to Sep 30, 2026 10.5B USD − same period a year earlier to Sep 30, 2025 10.0B USD = 14.2B USD
  • Net income: fiscal year to Dec 31, 2025 746.8M USD + year to date to Sep 30, 2026 685.9M USD − same period a year earlier to Sep 30, 2025 512.6M USD = 920.1M USD
  • Operating cash flow: fiscal year to Dec 31, 2025 1.9B USD + year to date to Sep 30, 2026 1.3B USD − same period a year earlier to Sep 30, 2025 1.3B USD = 1.9B USD
  • Capital expenditure: fiscal year to Dec 31, 2025 575.9M USD + year to date to Sep 30, 2026 431.3M USD − same period a year earlier to Sep 30, 2025 430.4M USD = 576.8M USD
By quarter (latest first, amounts in USD)
QuarterRevenuevs. year agoNet incomeMargin
Jul–Sep 263.6B+4.6%222.9M6.2%
Apr–Jun 263.6B+5.2%265.4M7.5%
Jan–Mar 263.4B+6.0%197.5M5.8%
Oct–Dec 25*3.6B+9.9%234.2M6.5%
Jul–Sep 253.4B+4.8%150.3M4.4%
Apr–Jun 253.4B+6.1%199.3M5.9%
Jan–Mar 253.2B+5.0%162.9M5.1%
Oct–Dec 24*3.3B+4.7%259.3M7.9%

Trailing 12 months = last fiscal year + the period since the start of the current fiscal year − the same period a year earlier, each from the first filing. P/E, PEG and the quality checks still use the last fiscal year.

Each quarter is compared with the same quarter a year earlier.

* derived: fiscal year minus the first 9 months.

As of: 12 months to Sep 30, 2026, filed on Oct 29, 2026 · Source: SEC filings (10-Q, 10-K)

Does the profit arrive as cash?

Earnings quality

Profit is backed by cash; interest is covered.

Cash flow ÷ profit
1.75x
backed from 1.0 · 3 years: 1.82x
Interest coverage
3.8x
well covered from 5 · 3 years: 4.3x
Tax rate
21.8%
for information only · 3 years: 19.6%
More depth

Calculation for fiscal year 2025

  • Operating cash flow 1.9B USD ÷ group profit incl. minority interests 1.1B USD = 1.75x
  • Operating income 2.0B USD ÷ Interest expense 539.9M USD = 3.8x
  • Taxes 293.1M USD ÷ profit before tax 1.3B USD = 21.8%
By fiscal year
FYCash flow ÷ profitInterest coverageTax rate
20251.75x3.8x21.8%
20241.62x4.8x18.3%
20232.15x4.3x18.7%
20222.00x3.9x20.5%
20211.59x6.7x20.2%

How it is rated: cash flow ÷ profit from 1.0 “backed by cash”, below 0.8 “profit well above the cash coming in”; interest coverage from 5 “well covered”, below 2 “thinly covered”. The tax rate is only shown.

Cash flow ÷ profit uses group profit incl. minority interests, because cash flow also covers the whole group. Profit before tax as reported to the SEC, otherwise approximated. “3 years” = sums of the last three fiscal years – only if every year is reported and the figures have the same origin; for cash flow only with a profit in every year.

As of fiscal year 2025 · Source: SEC filings

How even were the last years?

Consistency

In 10 fiscal years no loss year; 2 years with lower revenue across 9 years with a prior-year figure.

Loss years
0 of 10
net income below zero
Years with lower revenue
2 of 9
revenue below the prior year
Net margin range
7.0 percentage points
from 1.4% to 8.4%
Net margin by fiscal year · ▾ revenue below the prior year
More depth
By fiscal year
FYRevenue vs. prior yearNet margin
2025+6.5%5.5%
2024+5.6%7.3%
2023+4.6%5.7%
2022−0.1%4.8%
2021+0.6%8.4%
2020+1.4%6.7%
2019−0.1%7.1%
2018+4.9%1.4%
2017+1.6%6.1%
2016–8.2%

Loss year: net income below zero. Lower revenue: revenue below the prior year. Range: highest minus lowest net margin; margins beyond ±200% do not count. No score – only the reported figures.

As of fiscal years 2016–2025 · Source: SEC filings

Figures over time

Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.

Money flow in fiscal year 2025

Of 100 USD of revenue, 15.0 USD operating income and 5.5 USD net income remained.

Money flow as a table
Fiscal year 2025, amounts in USD, share of revenue
ItemAmountof revenue
Revenue13.6B USD100.0%
Operating income2.0B USD15.0%
Cost of revenue and operating expenses11.6B USD85.0%
Net income746.8M USD5.5%
Interest expense539.9M USD4.0%
Taxes293.1M USD2.1%
Other463.8M USD3.4%

Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.

Margins

The operating margin stayed roughly the same in 5 years (15.0%).

Operating marginNet margin
  1. Fiscal year 2016: Operating margin 17.7% · Net margin 8.2%
  2. Fiscal year 2017: Operating margin 16.7% · Net margin 6.1%
  3. Fiscal year 2018: Operating margin 13.4% · Net margin 1.4%
  4. Fiscal year 2019: Operating margin 14.4% · Net margin 7.1%
  5. Fiscal year 2020: Operating margin 14.7% · Net margin 6.7%
  6. Fiscal year 2021: Operating margin 15.5% · Net margin 8.4%
  7. Fiscal year 2022: Operating margin 11.5% · Net margin 4.8%
  8. Fiscal year 2023: Operating margin 13.2% · Net margin 5.7%
  9. Fiscal year 2024: Operating margin 16.3% · Net margin 7.3%
  10. Fiscal year 2025: Operating margin 15.0% · Net margin 5.5%

Returns

Return on equity rose in 5 years from 4.3% to 65.5%.

Return on equityReturn on assets Return on equity hidden where equity is below 5% of total assets.
  1. Fiscal year 2016: Return on equity 18.9% · Return on assets 4.7%
  2. Fiscal year 2017: Return on equity 14.1% · Return on assets 3.5%
  3. Fiscal year 2018: Return on equity 4.3% · Return on assets 0.8%
  4. Fiscal year 2019: Return on equity 38.0% · Return on assets 4.7%
  5. Fiscal year 2020: Return on equity 55.9% · Return on assets 4.6%
  6. Fiscal year 2021: Return on equity not available · Return on assets 5.7%
  7. Fiscal year 2022: Return on equity not available · Return on assets 3.3%
  8. Fiscal year 2023: Return on equity 65.5% · Return on assets 4.1%
  9. Fiscal year 2024: Return on equity not available · Return on assets 5.4%
  10. Fiscal year 2025: Return on equity not available · Return on assets 4.3%

Equity and long-term debt

The equity ratio fell in 5 years from 8.1% to −3.7%.

EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.
  1. Fiscal year 2016: Equity 4.6B USD · Long-term debt 9.1B USD
  2. Fiscal year 2017: Equity 4.7B USD · Long-term debt 9.3B USD
  3. Fiscal year 2018: Equity 3.7B USD · Long-term debt 10.1B USD
  4. Fiscal year 2019: Equity 2.1B USD · Long-term debt 8.1B USD
  5. Fiscal year 2020: Equity 1.4B USD · Long-term debt 8.1B USD
  6. Fiscal year 2021: Equity 755.5M USD · Long-term debt 8.9B USD
  7. Fiscal year 2022: Equity 712.3M USD · Long-term debt 8.9B USD
  8. Fiscal year 2023: Equity 1.1B USD · Long-term debt 8.4B USD
  9. Fiscal year 2024: Equity 121.1M USD · Long-term debt 9.4B USD
  10. Fiscal year 2025: Equity −651.1M USD · Long-term debt 10.3B USD

Liquidity (current ratio)

The current ratio stayed roughly the same in 5 years (1.29).

Current ratio
  1. Fiscal year 2016: Current ratio 1.48
  2. Fiscal year 2017: Current ratio 2.88
  3. Fiscal year 2018: Current ratio 1.72
  4. Fiscal year 2019: Current ratio 1.56
  5. Fiscal year 2020: Current ratio 1.27
  6. Fiscal year 2021: Current ratio 1.32
  7. Fiscal year 2022: Current ratio 1.20
  8. Fiscal year 2023: Current ratio 1.19
  9. Fiscal year 2024: Current ratio 1.26
  10. Fiscal year 2025: Current ratio 1.29

Cash flow

Free cash flow stayed roughly the same in 5 years (1.3B USD).

Operating cash flowCapital expenditureFree cash flow in USD
  1. Fiscal year 2016: Operating cash flow 2.0B USD · Capital expenditure 829.1M USD · Free cash flow 1.1B USD
  2. Fiscal year 2017: Operating cash flow 1.9B USD · Capital expenditure 905.3M USD · Free cash flow 1.0B USD
  3. Fiscal year 2018: Operating cash flow 1.8B USD · Capital expenditure 987.1M USD · Free cash flow 784.5M USD
  4. Fiscal year 2019: Operating cash flow 2.1B USD · Capital expenditure 766.5M USD · Free cash flow 1.3B USD
  5. Fiscal year 2020: Operating cash flow 2.0B USD · Capital expenditure 674.5M USD · Free cash flow 1.3B USD
  6. Fiscal year 2021: Operating cash flow 1.9B USD · Capital expenditure 641.5M USD · Free cash flow 1.3B USD
  7. Fiscal year 2022: Operating cash flow 1.6B USD · Capital expenditure 603.4M USD · Free cash flow 961.1M USD
  8. Fiscal year 2023: Operating cash flow 2.1B USD · Capital expenditure 568.0M USD · Free cash flow 1.5B USD
  9. Fiscal year 2024: Operating cash flow 2.0B USD · Capital expenditure 555.4M USD · Free cash flow 1.5B USD
  10. Fiscal year 2025: Operating cash flow 1.9B USD · Capital expenditure 575.9M USD · Free cash flow 1.3B USD

Share count

The share count fell in 5 years by 38.1% (mostly through share repurchases).

Diluted share count
  1. Fiscal year 2016: Diluted share count 204.9M
  2. Fiscal year 2017: Diluted share count 191.3M
  3. Fiscal year 2018: Diluted share count 172.4M
  4. Fiscal year 2019: Diluted share count 153.8M
  5. Fiscal year 2020: Diluted share count 122.6M
  6. Fiscal year 2021: Diluted share count 109.9M
  7. Fiscal year 2022: Diluted share count 95.8M
  8. Fiscal year 2023: Diluted share count 93.2M
  9. Fiscal year 2024: Diluted share count 87.3M
  10. Fiscal year 2025: Diluted share count 75.9M

From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.

Metrics chart

Up to three metrics stacked over the same fiscal years – so you see at a glance whether they rise together or drift apart. Point at a year to read it in every panel.

Metrics, up to 3 – to switch, deselect one first

Premium Line of a second stock for comparison

Revenue

Revenue rose in 5 years from 11.6B USD to 13.6B USD.

DVA in USD
  1. Fiscal year 2016: DVA 10.7B USD
  2. Fiscal year 2017: DVA 10.9B USD
  3. Fiscal year 2018: DVA 11.4B USD
  4. Fiscal year 2019: DVA 11.4B USD
  5. Fiscal year 2020: DVA 11.6B USD
  6. Fiscal year 2021: DVA 11.6B USD
  7. Fiscal year 2022: DVA 11.6B USD
  8. Fiscal year 2023: DVA 12.1B USD
  9. Fiscal year 2024: DVA 12.8B USD
  10. Fiscal year 2025: DVA 13.6B USD

Earnings per share

Earnings per share rose in 5 years from 6.31 USD to 9.84 USD.

DVA USD per share
  1. Fiscal year 2016: DVA 4.29 USD
  2. Fiscal year 2017: DVA 3.47 USD
  3. Fiscal year 2018: DVA 0.92 USD
  4. Fiscal year 2019: DVA 5.27 USD
  5. Fiscal year 2020: DVA 6.31 USD
  6. Fiscal year 2021: DVA 8.90 USD
  7. Fiscal year 2022: DVA 5.85 USD
  8. Fiscal year 2023: DVA 7.42 USD
  9. Fiscal year 2024: DVA 10.73 USD
  10. Fiscal year 2025: DVA 9.84 USD

Share count

The share count fell in 5 years by 38.1% (mostly through share repurchases).

DVA
  1. Fiscal year 2016: DVA 204.9M
  2. Fiscal year 2017: DVA 191.3M
  3. Fiscal year 2018: DVA 172.4M
  4. Fiscal year 2019: DVA 153.8M
  5. Fiscal year 2020: DVA 122.6M
  6. Fiscal year 2021: DVA 109.9M
  7. Fiscal year 2022: DVA 95.8M
  8. Fiscal year 2023: DVA 93.2M
  9. Fiscal year 2024: DVA 87.3M
  10. Fiscal year 2025: DVA 75.9M

Source: SEC filings, fiscal years up to Dec 31, 2025. The same figures as in the sections of this page, per fiscal year as first reported. Describes the reported figures – not investment advice.

How reliable is the dividend?

Dividend at a glance

The company paid no dividend in fiscal year 2025.

As of fiscal year 2025 · Source: SEC filings

Valued higher or lower than usual?

Valuation against its own history

The P/E is about at its own median of the 5 fiscal years before.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

Source: SEC filings and our daily candles

Dividends and share repurchases

How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.

Dividend per share
none no dividend in the last fiscal year
To shareholders (5 years)
5.3B USD 100% through repurchases
Share count over 5 years
−38.1% fewer shares – each share is a larger stake

What goes back to shareholders

Over 5 years, 5.3B USD went back to shareholders, 100% of it through share repurchases. That is 81% of the free cash flow of those years.

Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USD
  1. Fiscal year 2016: Dividends paid not available · Share repurchases 1.1B USD · New shares issued (including employee plans) not available · Free cash flow 1.1B USD
  2. Fiscal year 2017: Dividends paid not available · Share repurchases 802.9M USD · New shares issued (including employee plans) not available · Free cash flow 1.0B USD
  3. Fiscal year 2018: Dividends paid 0.0 USD · Share repurchases 1.2B USD · New shares issued (including employee plans) not available · Free cash flow 784.5M USD
  4. Fiscal year 2019: Dividends paid 0.0 USD · Share repurchases 2.4B USD · New shares issued (including employee plans) not available · Free cash flow 1.3B USD
  5. Fiscal year 2020: Dividends paid 0.0 USD · Share repurchases 1.5B USD · New shares issued (including employee plans) not available · Free cash flow 1.3B USD
  6. Fiscal year 2021: Dividends paid 0.0 USD · Share repurchases 1.5B USD · New shares issued (including employee plans) not available · Free cash flow 1.3B USD
  7. Fiscal year 2022: Dividends paid 0.0 USD · Share repurchases 802.2M USD · New shares issued (including employee plans) not available · Free cash flow 961.1M USD
  8. Fiscal year 2023: Dividends paid 0.0 USD · Share repurchases 272.2M USD · New shares issued (including employee plans) not available · Free cash flow 1.5B USD
  9. Fiscal year 2024: Dividends paid 0.0 USD · Share repurchases 1.4B USD · New shares issued (including employee plans) not available · Free cash flow 1.5B USD
  10. Fiscal year 2025: Dividends paid 0.0 USD · Share repurchases 1.3B USD · New shares issued (including employee plans) not available · Free cash flow 1.3B USD

Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.

Valuation over time

Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.

Sector comparison

DaVita next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.

Sector comparison DVA, sector Health Care; last row: sector median
Symbol Revenue (FY) Growth 5 yrsGross marginOp. marginNet marginROEEquity ratioFCF marginPiotroski
AMGN Amgen 36.8B USD +7.6%67.2%24.7%21.0%89.1%9.6%22.0%7/9
MDT Medtronic 36.4B USD +3.8%65.0%17.8%13.2%9.7%53.2%14.9%7/9
GILD Gilead Sciences 29.4B USD +3.6%78.8%34.0%28.9%37.5%38.5%32.1%8/9
SYK Stryker Corporation 25.1B USD +11.8%64.0%19.5%12.9%14.5%46.9%17.1%6/9
DHR Danaher Corporation 24.6B USD +2.0%59.1%19.1%14.7%6.9%62.9%21.4%7/9
REGN Regeneron Pharmaceuticals 14.3B USD +11.0%–24.9%31.4%14.4%77.1%28.4%–
DVA DaVita this stock 13.6B USD +3.4%–15.0%5.5%–−3.7%9.6%–
VRTX Vertex Pharmaceuticals 12.0B USD +14.1%86.2%34.8%32.9%21.2%72.8%26.6%–
ISRG Intuitive Surgical 10.1B USD +18.2%66.0%29.3%28.4%16.0%87.1%24.7%–
Median of the sector 27 symbols 44.3B USD +8.4%67.6%17.8%13.2%14.3%38.4%14.7%7/9

Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).

Compare with the closest peer in the sector DVA next to REGN – quality checks, metrics and depth side by side.

Figures of the last fiscal year from SEC annual reports (peers as of Nov 22, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 26 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light yellow: below sector

+3.4% per year, last 5 years

Sector Health Care: median +8.5% (25 symbols)

What does this mean? Revenue: over 5 years it grew by 3.4% per year on average, but more slowly than the median company in the sector (+8.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light red: shrinking

−0.7% per year, last 5 years

Sector Health Care: median +5.5% (20 symbols)

per share: +9.3% per year (5 years, split-adjusted)

What does this mean? Total net income: over 5 years it fell by 0.7% per year on average. The median company in the sector reached +5.5% per year.

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light yellow: below sector

5.5% last fiscal year

Sector Health Care: median 13.9% (26 symbols)

What does this mean? Of every 100 USD in revenue, 5.47 USD remained as profit – less than the median company in the sector (13.9%). Five years ago the margin was 6.7%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light gray: negative equity

– latest balance sheet

Sector Health Care: median 0.66 (19 symbols)

What does this mean? Equity is negative (e.g. due to share buybacks). A debt-to-equity ratio cannot be formed meaningfully then.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light gray: none found

– Dividend / earnings per share

Sector Health Care: median 56% (16 symbols)

What does this mean? The loaded SEC filings of the last two fiscal years contain no dividend per share. Either the company pays none, or it reports it under a different tag.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light green: profit every year

10 of 10 fiscal years with a profit

What does this mean? In 10 of the last 10 fiscal years the bottom line showed a profit. There were no losses in this period.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
13.6B USD
Revenue vs. prior year
+6.5%
Net income (FY)
746.8M USD
Net income vs. prior year
−20.2%
EPS (FY)
9.84 USD
Superinvestors holding
3 of 26
Fiscal year to Dec 31, 2025 · 10-K filed Feb 11, 2026 · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). Superinvestors: 26 tracked investors per 13F filing (as of quarter end, filed up to 45 days later); weight and change per investor in the card “Which superinvestors hold …?”.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 31, 2025 13.6B746.8M 5.5% 9.84 – –
2024Dec 31, 2024 12.8B936.3M 7.3% 10.73 – –
2023Dec 31, 2023 12.1B691.5M 5.7% 7.42 – –
2022Dec 31, 2022 11.6B560.4M 4.8% 5.85 – –
2021Dec 31, 2021 11.6B978.5M 8.4% 8.90 – –
2020Dec 31, 2020 11.6B773.6M 6.7% 6.31 – –
2019Dec 31, 2019 11.4B811.0M 7.1% 5.27 – –
2018Dec 31, 2018 11.4B159.4M 1.4% 0.92 – –
2017Dec 31, 2017 10.9B663.6M 6.1% 3.47 – –
2016Dec 31, 2016 10.7B879.9M 8.2% 4.29 – –
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q3/26Sep 30, 2026 3.6B222.9M 6.2% 3.40 – –
Q2/26Jun 30, 2026 3.6B265.4M 7.5% 4.02 – –
Q1/26Mar 31, 2026 3.4B197.5M 5.8% 2.87 – –
Q4/25*Dec 31, 2025 3.6B234.2M 6.5% – – –
Q3/25Sep 30, 2025 3.4B150.3M 4.4% 2.04 – –
Q2/25Jun 30, 2025 3.4B199.3M 5.9% 2.58 – –
Q1/25Mar 31, 2025 3.2B162.9M 5.1% 2.00 – –
Q4/24*Dec 31, 2024 3.3B259.3M 7.9% – – –
Q3/24Sep 30, 2024 3.3B214.7M 6.6% 2.50 – –
Q2/24Jun 30, 2024 3.2B222.7M 7.0% 2.50 – –
Q1/24Mar 31, 2024 3.1B239.6M 7.8% 2.65 – –
Q4/23*Dec 31, 2023 3.1B150.7M 4.8% – – –

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Information only – does not affect the other analysis methods, not investment advice.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $69.0M1 person −$69.0M
6 months $00 people $123.3M3 people −$123.3M
12 months $00 people $523.4M6 people −$523.4M

Latest transactions

  • Oct 27, 2026 Berkshire Hathaway Inc 10% owner Open-market sale 382,563 shares · $69.0M · SEC
  • Jul 31, 2026 Berkshire Hathaway Inc 10% owner Open-market sale 182,980 shares · $36.5M · SEC
  • Jun 16, 2026 Rodriguez Javier Chief executive (CEO), Director Open-market sale 39,407 shares · $8.2M · SEC
  • Jun 15, 2026 Waters Kathleen Alyce Officer Open-market sale 6,455 shares · $1.4M · SEC
  • Jun 15, 2026 Waters Kathleen Alyce Officer Open-market sale 8,950 shares · $1.9M · SEC
  • Jun 15, 2026 Rodriguez Javier Chief executive (CEO), Director Open-market sale 30,000 shares · $6.3M · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Which superinvestors hold DaVita?

All superinvestor portfolios

3 of 26 tracked superinvestors report a position.

Superinvestors with a position in DaVita, weight in each portfolio
InvestorWeight in portfoliovs. previous quarterAs of
Warren Buffett Berkshire Hathaway Inc 1.7% −0.6% reduced Q3 2026
Steve Cohen Point72 Asset Management 0.2% new Q3 2026
Bridgewater Associates < 0.1% +255.4% increased Q3 2026

Sold out in the latest quarter: Renaissance Technologies, Paul Tudor Jones.

Source: 13F filing with the US Securities and Exchange Commission, latest filing dated Nov 16, 2026. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.

Trend score –

We do not calculate a trend score for symbols in the extended universe.

Volatility and trend strength

ADX 14 (trend strength)–
Price change 60 days–

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

No recent news found. News is loaded automatically three times a day for trend stocks, symbols with a current Elliott setup and favorites.

Posts

No posts on DVA yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: DVA

Alerts with a free account: we send you an email as soon as the price moves above or below your level.

Checked after every data update: crypto hourly, stocks twice a day, precious metals every 4 hours on trading days, extended universe on weekdays after the close (daily candles) – not in real time.

↑ ↓ select · Enter open · Esc close